Laboratory Corp. of America Holdings | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
404
580
716
434
317
427
Total Accounts Receivable
785
816
1,375
1,519
1,717
1,862
Inventories
137
140
191
205
228
237
Other Current Assets
107
158
339
321
421
309
Total Current Assets
1,432
1,693
2,621
2,479
2,683
2,835
Net Property, Plant & Equipment
707
787
1,747
1,719
1,749
1,785
Total Investments and Advances
89
93
58
58
58
61
Intangible Assets
4,595
4,575
9,526
9,825
11,871
11,271
Other Assets
143
155
150
165
205
232
Total Assets
6,966
7,302
14,105
14,247
16,568
16,185
ST Debt & Current Portion LT Debt
111
347
424
550
418
Accounts Payable
305
282
497
508
663
Income Tax Payable
34
38
84
61
65
Other Current Liabilities
286
309
695
709
901
Total Current Liabilities
736
976
1,701
1,828
2,046
Long-Term Debt
2,889
2,683
5,940
5,300
6,345
Provision for Risks & Charges
196
196
216
269
235
Deferred Taxes
564
530
1,179
2
2
Other Liabilities
71
78
107
1,330
1,091
Total Liabilities
4,455
4,464
9,145
8,726
9,717
Common Equity (Total)
2,491
2,821
4,945
5,506
6,830
Total Shareholders' Equity
2,491
2,821
4,945
5,506
6,830
Total Equity
2,511
2,838
4,960
5,521
6,851
Liabilities & Shareholders' Equity
6,966
7,302
14,105
14,247
16,568
Accumulated Minority Interest
19
18
15
15
21

About Laboratory

View Profile
Address
358 South Main Street
Burlington North Carolina 27215
United States
Employees -
Website http://www.labcorp.com
Updated 07/08/2019
Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.